DS
GRCL

David Shaw’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

David Shaw’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,356
Closed -$200K – 5333
2021
Q2 		$200K Buy
+15,356
New +$206K ﹤0.01% 4452

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

David Shaw's GRCL Position: Q3 2021 in Review

David Shaw sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q3 2021, closing a stake of 15,356 shares — an estimated $200K sold.

David Shaw first reported a position in GRCL in Q2 2021 and held it in 1 quarter. The position peaked at $200K in Q2 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q3 2021.

  • David Shaw reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q3 2021 after selling out during the quarter.
  • David Shaw sold 15,356 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2021, an estimated $200K.
  • David Shaw first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2021 and held it in 1 quarter.
  • David Shaw's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $200K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.